Protalix BioTherapeutics, Inc. (NYSE:PLX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 84.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 45,952 shares of the company's stock after selling 244,307 shares during the period. Jane Street Group LLC owned 0.06% of Protalix BioTherapeutics worth $47,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PLX. Cubist Systematic Strategies LLC acquired a new stake in shares of Protalix BioTherapeutics in the second quarter worth approximately $37,000. AQR Capital Management LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at $80,000. Squarepoint Ops LLC increased its holdings in shares of Protalix BioTherapeutics by 673.3% during the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company's stock worth $161,000 after buying an additional 119,949 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company's stock worth $444,000 after buying an additional 33,969 shares during the period. Hedge funds and other institutional investors own 16.53% of the company's stock.

Protalix BioTherapeutics Stock Performance

PLX remained flat at $2.17 during trading on Thursday. 511,428 shares of the company's stock traded hands, compared to its average volume of 764,203. Protalix BioTherapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $2.36. The stock's 50-day moving average is $1.78 and its 200 day moving average is $1.31. The stock has a market capitalization of $159.78 million, a price-to-earnings ratio of -16.69 and a beta of 0.71.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Protalix BioTherapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, December 12th.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.